Besic Nikola, Vidergar-Kralj Barbara, Frkovic-Grazio Snjezana, Movrin-Stanovnik Tadeja, Auersperg Marija
Department of Surgical Oncology, Institute of Oncology, Ljubljana, Slovenia.
Thyroid. 2003 Jun;13(6):577-84. doi: 10.1089/105072503322238845.
It is generally believed that Hürthle cell thyroid carcinoma (HCTC) does not accumulate radioactive iodine (RAI). The aim of our retrospective study was to find out if, after thyroid surgery and RAI ablation of the thyroid remnant, the metastatic or recurrent HCTC accumulates RAI. We reviewed the charts of 48 patients with histopathologically verified HCTC, who were treated at the Institute of Oncology in Ljubljana, Slovenia, from 1972 to 2000. In 16 patients (11 women, five men; 47-77 years old), who had distant metastases at presentation (eight patients) or recurrence (eight patients), whole-body RAI scanning was performed after the withdrawal of thyroid hormone replacement. Whenever RAI uptake was confirmed, the therapy with 5.6 GBq of RAI was performed. In 11 of 16 patients, the uptake (range 0.1-12%) of RAI was confirmed. Altogether, 46 therapeutic applications of RAI were given. We conclude that whole-body scanning with RAI should be performed in HCTC. RAI may be effective in the treatment of HCTC.
一般认为，许特莱细胞甲状腺癌（HCTC）不摄取放射性碘（RAI）。我们这项回顾性研究的目的是，探究在甲状腺手术及对甲状腺残余组织进行RAI消融后，转移性或复发性HCTC是否会摄取RAI。我们回顾了1972年至2000年期间在斯洛文尼亚卢布尔雅那肿瘤研究所接受治疗的48例经组织病理学证实为HCTC患者的病历。16例患者（11名女性，5名男性；年龄47 - 77岁），初诊时已有远处转移（8例）或复发（8例），在停用甲状腺激素替代治疗后进行了全身RAI扫描。一旦确认有RAI摄取，即给予5.6 GBq的RAI治疗。16例患者中有11例确认有RAI摄取（摄取范围为0.1% - 12%）。总共进行了46次RAI治疗应用。我们得出结论，HCTC患者应进行RAI全身扫描。RAI可能对HCTC治疗有效。
